Streptococcus, Group B (2018 Data)
Antibiotic |
% Susceptible |
Antibiotic |
% Susceptible |
|
Ampicillin | 100 |
Imipenem | + |
|
Azithromycin | 43 |
Levofloxacin | 100 |
|
Aztreonam | - |
Meropenem | + |
|
Cefazolin | 100 |
Moxifloxacin | +
|
|
Cefepime | + |
Nitrofurantoin | &
|
|
Ceftazidime | + |
Oxacillin/Naf | + |
|
Ceftriaxone | 100 |
Penicillin | 99 |
|
Cefuroxime | + |
Piperacillin | +
|
|
Ciprofloxacin | +/- |
Piperacillin/tazo | + |
|
Clarithromycin | + |
Ticarcillin/Clav | + |
|
Clindamycin | 55 |
Tobramycin | - |
|
Doxycycline | - |
TMP/SMX | - |
|
Erythromycin | +/- |
Unasyn/Aug | + |
|
Gentamicin | - |
Vancomycin | 100 |
|
Number of isolates tested: 91
Comments: Beta streptococci remain reliably susceptible to beta lactam antibiotics including penicillin
For historical susceptibility data click here
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections